Based on this result, we evaluate the strategy of using pathological response-guided non-cross-resistant adjuvant chemotherapy for patients with HR + /HER2-/LN+ breast cancer who are non-responsive to primary chemotherapy. This evidence concerns the gene ERBB2 and breast cancer.